467 results on '"Chronic Hepatitis B"'
Search Results
2. A two-pronged strategy utilizing exosomes extracted from antigen-presenting cells to combat hepatitis B
3. The Influence of ESR2 Gene Polymorphisms on Susceptibility to Hepatitis B Virus-Related Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma
4. “Cherry blossom” in Kyoto brought hope to patients with chronic hepatitis B infection
5. Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis
6. HBeAg induces neutrophils activation impairing NK cells function in patients with chronic hepatitis B
7. Hepatitis B Virus Infection in Eastern Libya: Current Efforts for Overcoming Regional Barriers for Its Elimination
8. Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4
9. Association Between Serum Levels of Anti-heat Shock Protein 27 Antibody and Liver Cell Injury in Chronic Hepatitis B
10. Efficacy and Safety of Oxymatrine in the Treatment of Patients with Erythrodermic Psoriasis
11. Expanding the Donor Pool for Liver Transplantation: Assessing the Potential Use of HBV-Positive Allografts
12. Liver fibrosis showed a two-phase regression rate during long-term anti-HBV therapy by three-time biopsies assessments
13. Availability, price, and affordability of anti-hepatitis B virus drugs: a cross-sectional study in China
14. When to Stop Antiviral Therapy in HBeAg-Negative Patients with Chronic Hepatitis B?
15. Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B
16. Synthesis and photodynamic properties of 5-ALA/g-C3N4@1 supramolecular photosensitizer with potential application in chronic hepatitis B treatment
17. HBeAg-positive CHB patients with indeterminate phase associated with a high risk of significant fibrosis
18. Effect of dyslipidemia on HBsAg clearance in nucleos(t)ide analogues-experienced chronic hepatitis B patients treated with peginterferon alfa
19. Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis
20. Risk factors for significant histological changes in both HBeAg positive and negative treatment-naive chronic hepatitis B with persistently normal alanine aminotransferase level
21. The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment
22. Nucleos(t)ide analogs to treat patients with positive hepatitis B virus deoxyribonucleic acid and normal alanine transaminase: protocol for an open-label single-center randomized parallel controlled trial
23. Effects of tenofovir alafenamide fumarate on serum lipid profiles in patients with chronic hepatitis B
24. Efficacy of short-term Peg-IFN α-2b treatment in chronic hepatitis B patients with ultra-low HBsAg levels: a retrospective cohort study
25. Role of tenofovir dipivoxil in gut microbiota recovery from HBV-infection induced dysbiosis
26. Lymph node-targeted STING agonist nanovaccine against chronic HBV infection
27. Functional cure induced by tenofovir alafenamide plus peginterferon-alpha-2b in young children with chronic hepatitis B: a case series study
28. Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT
29. A non-invasive diagnostic nomogram for CHB-related early cirrhosis: a prospective study
30. The non-invasive serum biomarkers contributes to indicate liver fibrosis staging and evaluate the progress of chronic hepatitis B
31. Latest insights into the epidemiology, characteristics, and therapeutic strategies of chronic hepatitis B patients in indeterminate phase
32. Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase
33. A machine learning-based model analysis for serum markers of liver fibrosis in chronic hepatitis B patients
34. Noninvasive models for the prediction of liver fibrosis in patients with chronic hepatitis B
35. Correlation between quantitative HBsAg and quantitative HBV DNA in chronic hepatitis B patients: a systematic review and meta-analysis
36. Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma
37. Expression of 10 circulating cytokines/chemokines in HBV-related liver disease
38. Prevalence of metabolic syndrome among patients with hepatocellular carcinoma of different etiologies: a retrospective study
39. Successful therapy with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) does not guarantee amelioration of liver damage assessing by transient elastography. A retrospective - prospective multicenter study
40. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy
41. Hypermethylation of the glutathione peroxidase 4 gene promoter is associated with the occurrence of immune tolerance phase in chronic hepatitis B
42. Routine evaluation of HBV-specific T cell reactivity in chronic hepatitis B using a broad-spectrum T-cell epitope peptide library and ELISpot assay
43. A conceptual model for chronic hepatitis B and content validity of the Hepatitis B Quality of Life (HBQOL) instrument
44. Experience and impact of stigma in people with chronic hepatitis B: a qualitative study in Asia, Europe, and the United States
45. Characteristics and clinical treatment outcomes of chronic hepatitis B children with coexistence of hepatitis B surface antigen (HBsAg) and antibodies to HBsAg
46. Functional cure is associated with younger age in children undergoing antiviral treatment for active chronic hepatitis B
47. Interventions to Improve Surveillance for Hepatocellular Carcinoma in High-Risk Patients: A Scoping Review
48. Precision Management of Patients with HBV Infection
49. Update on HCC Surveillance in Patient With Hepatitis B Virus Infection With Focus on Biomarkers
50. Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.